H.R. 3 is the wrong path to lower drug costs - STAT

H.R. 3 is the wrong path to lower drug costs - STAT

Opinion: H.R. 3 is the wrong path to lower drug costs

By MIKE GUERRA

ZACH GIBSON/GETTY IMAGES

A new report shows that lowering drug costs in Medicare Part D by adopting international reference pricing would have a devastating effect on innovation.

READ MORE